If you take a look at Al Lewis' signature message, you'll see a Victor Hugo quote, "There is nothing so powerful as an idea whose time has come."
For a growing number of providers, plans and other organizations in the healthcare industry, disease management is indeed an idea whose time has come-and Lewis, founder and president of Disease Management Purchasing Consortium International (DMPC) and MHE Editorial Advisor, is credited by many as being a "Johnny Appleseed" who's taken it upon himself to plant and nourish the disease management concept.
The Disease Management Association of America, which Lewis founded seven years ago, defines disease management as "a system of coordinated healthcare interventions and communications for populations with conditions in which patient self-care efforts are significant." Disease management, says the association, "supports the physician or practitioner/patient relationship and plan of care; emphasizes prevention of exacerbations and complications utilizing evidence-based practice guidelines and patient empowerment strategies; and evaluates clinical, humanistic and economic outcomes on an ongoing basis with the goal of improving overall health."
Lewis, 49, founded DMPC in 1996. Prior to that, he served as chief executive officer of Peer Review Analysis Inc. and executive vice president of InterQual Inc. (now part of McKesson). He earned undergraduate and law degrees from Harvard University, Phi Beta Kappa, and a visiting scholar appointment at the Heller School for Social Policy at Brandeis University.
In December 2004, Lewis was designated No. 1 on Managed Healthcare Executive's overall list of the Most Influential People in Disease Management, and four years ago, Managed Healthcare Executive credited him with "inventing disease management."
Q. There must be reasons why you've been such a champion of the disease-management concept in the healthcare industry. Why do you feel so strongly that disease management is, as Victor Hugo put it, "an idea whose time has come?"
A. Plenty of people advocate for prevention, but for a private organization, the numbers aren't really there to go out and do primary prevention. Primary prevention is a public-health issue. My value-added for the DM field-and what makes it 'an idea whose time has come'-was to identify areas where prevention would be cost-effective for an insurer and also to measure that cost-effectiveness and get the vendors to guarantee it. It turns out that so-called secondary prevention-prevention in very high-risk people-is indeed quite cost-effective for a private payer.
Having now participated in many reconciliations, I am, if anything, even more passionate about DM. Time after time, one sees ROIs of 1 to 1.5 or higher, and you're getting these ROIs by making people healthier and more productive-a true win-win for everyone.
Q. How successful have you been in getting industry institutions and organizations to buy in to the concept of disease management? In other words, what's in it for them?
A. To paraphrase George Stephanopoulos, 'It's the economics, stupid.' Quality by itself doesn't sell-the CFO needs to approve these budgets, and they won't do that if they don't see an ROI.
My experience is quite consistent: If I can convince a payer that the economics are there, they will do disease management.
Conversations With Perry and Friends
April 14th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. His guest this episode is John Baackes, the former CEO of L.A. Care Health Plan.
Listen
Roflumilast Foam Showed Strong Results for Scalp and Body Psoriasis in Teens and Adults
May 7th 2025A new JAMA Dermatology study found that once-daily Zoryve (roflumilast) foam, 0.3%, safely and effectively reduced scalp and body plaque psoriasis symptoms in patients 12 and older, offering a convenient, and more tolerated treatment option that may boost adherence and quality of life.
Read More
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
Time Well Spent: Lung Cancer Trials Offer Improved Survival Without Added Burden
May 7th 2025Researchers are exploring the topic of "time toxicity" — how much time patients spend receiving care. This study is the first to directly compare time spent in care between clinical trial participants and routine care patients receiving the same treatments.
Read More
Depend on Biomakers, Not Symptoms, for Diagnosis, Early Treatment of GVHD, Experts Argue
May 7th 2025John Levine, M.D., a graft-versus-host-disease expert at the Icahn School of Medicine at Mount Sinai in New York, makes a case for biomarkers in a review article published in the American Journal of Hematology.
Read More